Patriot Financial Group Insurance Agency LLC Has $606,000 Position in GSK plc (NYSE:GSK)

Patriot Financial Group Insurance Agency LLC boosted its position in GSK plc (NYSE:GSK) by 9.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,910 shares of the pharmaceutical company’s stock after purchasing an additional 1,502 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in GSK were worth $606,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Sunbelt Securities Inc. boosted its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. Mesirow Financial Investment Management Inc. grew its position in GSK by 2.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after buying an additional 323 shares in the last quarter. Rehmann Capital Advisory Group increased its stake in GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after acquiring an additional 332 shares during the period. Investment Partners Asset Management Inc. raised its holdings in GSK by 2.3% in the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock valued at $636,000 after acquiring an additional 344 shares in the last quarter. Finally, Bond & Devick Financial Network Inc. lifted its position in shares of GSK by 5.4% during the 3rd quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock valued at $320,000 after acquiring an additional 400 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK stock opened at $35.12 on Wednesday. The company’s 50 day moving average price is $33.94 and its two-hundred day moving average price is $37.78. The firm has a market capitalization of $72.78 billion, a P/E ratio of 22.80, a P/E/G ratio of 1.31 and a beta of 0.63. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

Analysts Set New Price Targets

A number of brokerages recently commented on GSK. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.